ADVFN - Advanced Financial Network.
HOME» NYSE » J » JNJ Stock Price » JNJ Stock News

Johnson & Johnson Share News

 Johnson & Johnson Stock Price
JNJ Stock Price
 Johnson & Johnson Stock Chart
JNJ Stock Chart
 Johnson & Johnson Stock News
JNJ Stock News
 Johnson & Johnson Company Information
JNJ Company Information
 Johnson & Johnson Stock Trades
JNJ Stock Trades

Drug Contract Manufacturer Ben Venue To Exit Business

By Peter Loftus Of DOW JONES NEWSWIRES A Boehringer Ingelheim GmbH plant that has caused shortages in drug supplies will exit the pharmaceutical contract-manufacturing business as it faces a Canadian ban on the importation of some of its drugs. Boehringer's Ben Venue Laboratories unit, which manufactures injectable and inhaled drugs for major players including Pfizer Inc. (PFE) and Johnson & Johnson (JNJ), will exit the contract-manufacturing business in a transition over the next several years, spokesman Jason Kurtz said Friday. The move could compound recent drug shortages affecting numerous manufacturers, which have forced some U.S. hospitals to ration or restrict use of certain drugs, and sent patients on a hunt for pharmacies with drugs in stock. Ben Venue, which operates a plant in suburban Cleveland, will work with its customers to minimize supply disruptions. Other divisions of Germany's Boehringer Ingelheim will continue to perform contract-manufacturing services, Kurtz said. Canada's drug regulator, Health Canada, this week restricted imports of certain drugs made at Ben Venue's Ohio plant after identifying manufacturing deficiencies there, which the regulators said could affect product quality, according to a notice posted online. As a result, Health Canada only will allow the importation of 17 drugs treating serious or life-threatening conditions that are manufactured at the Ben Venue plant, for which there are no feasible alternatives. These include Pfizer's Torisel kidney-cancer treatment; Velcade, a multiple-myeloma treatment co-marketed by J&J and Takeda Pharmaceutical Co. (4502.TO, TKPYY); and Bristol-Myers Squibb Co.'s (BMY) BiCNU cancer drug. Health Canada said it hasn't identified any specific risk to health as a result of the manufacturing deficiencies at Ben Venue's Ohio plant. The regulator didn't identify in its online notice which Ben Venue-manufactured drugs won't be allowed into Canada; an agency spokeswoman didn't immediately have that information. In addition, European regulators have limited the import of drugs made at Ben Venue's plant to certain medically necessary products, said Ben Venue spokesman Kurtz. Problems at the Ben Venue plant have contributed to a supply shortage of J&J's Doxil treatment for ovarian cancer and multiple myeloma. Ben Venue said in July that it was experiencing manufacturing capacity restraints causing shortages for some products, which forced J&J to advise doctors not to start new patients on Doxil until the supply shortage could be resolved. J&J spokeswoman Lisa Vaga said the company will transition to another contract manufacturer, and that during the transition, Ben Venue has committed to giving highest priority to ensuring access to important drugs such as Doxil. J&J doesn't expect Velcade supply in Canada to be affected. Spokesmen for Bristol and Pfizer declined to comment. A list of the Ben Venue-manufactured drugs that will be allowed into Canada can be found here: The trade publication Contract Pharma reported Ben Venue's decision to exit the contract-manufacturing business Thursday. -Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Johnson & Johnson (JNJ)
10/20/201616:10:00Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter...
10/20/201606:32:00E.ON to Invest $500 Million in Illinois Wind Farm
10/19/201610:40:00Johnson & Johnson Opens New Global Services Center In Tampa...
10/19/201609:48:00Ortho Clinical Diagnostics to Present Data on Automation in Immunohematology...
10/19/201603:03:00J&J Brushes Off Pfizer's Challenge -- WSJ
10/18/201612:43:00J&J Brushes off Looming Biosimilar Competition -- 2nd Update
10/18/201609:15:00J&J Again Buoyed by Pharmaceuticals -- Update
10/18/201608:17:50Current Report Filing (8-k)
10/18/201608:10:00J&J Again Buoyed by Pharmaceuticals
10/18/201607:49:00Johnson & Johnson Again Buoyed by Pharmaceuticals
10/18/201606:40:00Johnson & Johnson Reports 2016 Third-Quarter Results:
10/17/201619:16:00Pfizer Plans to Launch Remicade Biosimilar in November -- Update
10/17/201618:40:00Depomed to Add Starboard Nominees
10/17/201618:40:00Pfizer Plans to Launch Remicade Biosimilar in November
10/17/201618:36:00JPMorgan Sees $1 Billion In Lost J&J Sales On Pfizer Biosimilar...
10/17/201618:06:00Pfizer Plans to Launch Remicade Biosimilar in November
10/07/201603:51:00Correction to AstraZeneca Story
10/07/201603:00:00AstraZeneca Signs $330 Million Deal with Johnson & Johnson Affiliate
10/04/201616:30:00J&J Warns Insulin Pump Vulnerable to Cyber Hacking
10/04/201616:26:00J&J Warns Insulin Pump Vulnerable to Cyber Hacking

Johnson & Johnson and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations